close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by C2N Diagnostics

News headline image
C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology
From C2N Diagnostics
Via Business Wire
News headline image
Alzheimer’s Disease Community Benefits as C2N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard
From C2N Diagnostics
Via Business Wire
News headline image
C2N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment1,2, Is Poised to Support Medical Community in Next Steps
From C2N Diagnostics
Via Business Wire
News headline image
C2N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion
From C2N Diagnostics
Via Business Wire
News headline image
C2N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023
From C2N Diagnostics
Via Business Wire
News headline image
International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference
From C2N Diagnostics
Via Business Wire
News headline image
C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health
From C2N Diagnostics
Via Business Wire
News headline image
C2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia
From C2N Diagnostics
Via Business Wire
Tickers ASX:HLS
News headline image
C2N’s New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment
From C2N Diagnostics
Via Business Wire
News headline image
C2N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field
From C2N Diagnostics
Via Business Wire
News headline image
JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease
From C2N Diagnostics
Via Business Wire
News headline image
C2N Achieves ISO 13485:2016 Certification; Latest Development for Leader in Brain Health Sector
From C2N Diagnostics
Via Business Wire
News headline image
Researchers to Present Multiple Studies at CTAD and GSA Meetings About the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnoses
From C2N Diagnostics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today